Citadel Advisors’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History

Citadel Advisors’s Portfolio UBIO Stock Details UBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-9,976	Closed	-$212K	–	8025
2016 Q2	$212K	Buy	+9,976	New	+$253K	﹤0.01%	5750

Other funds holding UBIO

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's UBIO Position: Q3 2016 in Review

Citadel Advisors sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q3 2016, closing a stake of 9,976 shares — an estimated $212K sold.

Citadel Advisors first reported a position in UBIO in Q2 2016 and held it in 1 quarter. The position peaked at $212K in Q2 2016. 7 funds tracked by Wall St. Rank hold UBIO as of Q3 2016.

Citadel Advisors reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q3 2016 after selling out during the quarter.
Citadel Advisors sold 9,976 Proshares UltraPro NASDAQ Biotechnology shares in Q3 2016, an estimated $212K.
Citadel Advisors first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q2 2016 and held it in 1 quarter.
Citadel Advisors's Proshares UltraPro NASDAQ Biotechnology position peaked at $212K in Q2 2016.
7 funds tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q3 2016.

Based on Citadel Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.